Akeso Inc
HKEX:9926
Intrinsic Value
Akeso, Inc. is a clinical-stage biopharmaceutical company, which committed to in-house discovery, development and commercialization of therapies. [ Read More ]
The intrinsic value of one Akeso Inc stock under the Base Case scenario is 42.4 HKD. Compared to the current market price of 48.45 HKD, Akeso Inc is Overvalued by 12%.
Valuation Backtest
Akeso Inc
Run backtest to discover the historical profit from buying and selling Akeso Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Akeso Inc
Current Assets | 5.7B |
Cash & Short-Term Investments | 2.4B |
Receivables | 295.6m |
Other Current Assets | 3B |
Non-Current Assets | 3.5B |
Long-Term Investments | 305.5m |
PP&E | 3.2B |
Intangibles | 6.4m |
Current Liabilities | 1.2B |
Accounts Payable | 354.8m |
Other Current Liabilities | 849.8m |
Non-Current Liabilities | 3.3B |
Long-Term Debt | 2.6B |
Other Non-Current Liabilities | 698.3m |
Earnings Waterfall
Akeso Inc
Revenue
|
4.5B
CNY
|
Cost of Revenue
|
-133.2m
CNY
|
Gross Profit
|
4.4B
CNY
|
Operating Expenses
|
-2.2B
CNY
|
Operating Income
|
2.2B
CNY
|
Other Expenses
|
-188.8m
CNY
|
Net Income
|
2B
CNY
|
Free Cash Flow Analysis
Akeso Inc
Profitability Score
Profitability Due Diligence
Akeso Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
Akeso Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Akeso Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
Akeso Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Akeso Inc
According to Wall Street analysts, the average 1-year price target for Akeso Inc is 61.55 HKD with a low forecast of 50.5 HKD and a high forecast of 73.5 HKD.
Shareholder Return
Price
Akeso Inc
Average Annual Return | 31.92% |
Standard Deviation of Annual Returns | 48.27% |
Max Drawdown | -82% |
Market Capitalization | 40.7B HKD |
Shares Outstanding | 865 857 024 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Akeso, Inc. is a clinical-stage biopharmaceutical company, which committed to in-house discovery, development and commercialization of therapies. The company is headquartered in Zhongshan, Guangdong. The company went IPO on 2020-04-24. The firm is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The firm's main products include AK104, AK105, AK112 and AK109. The firm conducts its businesses within the China market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Akeso Inc stock under the Base Case scenario is 42.4 HKD.
Compared to the current market price of 48.45 HKD, Akeso Inc is Overvalued by 12%.